Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 20Gemcitabine 10Nivolumab 8Irinotecan 8atezolizumab 7durvalumab 6Docetaxel 6sargramostim 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5aldesleukin 4Psychiatric Rehabilitation 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cisplatin 4tislelizumab 3spartalizumab 3avelumab 3Topotecan 3Therapeutics 3Polymerase Chain Reaction 3Carboplatin 3Bevacizumab 3tremelimumab 2talazoparib 2surufatinib 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × BAY 1895344 × Gastrointestinal × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡